Avid Bioservices Inc (CDMO)

[biopharm]

Wolchok has never mentioned Peregrine and Bavi by name.

I would read more of the PRs and especially abstract #1651 at 2017 AACR. FYI: Bavituximab is a PS targeting drug and below is the PR provided by Peregrine Pharmaceuticals. I would read my prior post that provides the substance where Dr Jedd Wolchok knows how bad Cytokine storms are for new IO drugs and now one can easily see Dr Wolchok was seeing PS Targeting as a great opportunity back in May 2015 and finally in abstract #1651 he takes the next step and now, who do you think will partner with Peregrine and MSK for a trial or two ?? : )

May 29, 2015

Peregrine Pharmaceuticals Enters Into Research Collaboration to Investigate Novel PS-Targeting Immunotherapy Combinations

Research Collaboration to Focus on Exploring Potential Combinations of PS-Targeting Agents Including Bavituximab With Other Immune Modulators

..
..
"The phosphatidylserine (PS) signaling pathway is a very interesting target for modulating the immune system's response to cancer. We look forward to exploring the potential of PS-targeting agents alone and with other immune modulators that may lead to novel advances in cancer therapy," said Dr. Wolchok.
..
..
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=915472